A novel bio-psychosocial-behavioral treatment model in schizophrenia

Yong Ku Kim, Joonho Choi, Seon Cheol Park

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Despite the substantial burden of illness in schizophrenia, there has been a discrepancy between the beneficial effects of an increased use of antipsychotic medications and achieving limited recovery or remission. Because the focus of the most common antipsychotic medications is on dopamine, which is associated with positive symptoms, there is an unmet need for patients with negative symptoms. Since cognitive and negative symptoms rather than positive symptoms are more closely associated with psychosocial impairments in patients with schizophrenia, the non-dopaminergic systems including glutamate and -aminobutyric acid (GABA) of the prefrontal cortex should be of concern as well. The balance of excitation and inhibition has been associated with epigenetic modifications and thus can be analyzed in terms of a neurodevelopmental and neural circuitry perspective. Hence, a novel bio-psychosocial-behavioral model for the treatment of schizophrenia is needed to account for the non-dopaminergic systems involved in schizophrenia, rather than dopaminergic mechanisms. This model can be understood from the viewpoint of neurodevelopment and neural circuitry and should include the staging care, personalized care, preventive care, reducing the cognitive deficits, and reducing stigma. Thomas R. Insel proposed this as a goal for schizophrenia treatment to be achieved by 2030.

Original languageEnglish
Article number734
JournalInternational Journal of Molecular Sciences
Volume18
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

schizophrenia
Antipsychotic Agents
Schizophrenia
Aminobutyrates
Glutamic Acid
Dopamine
Recovery
Acids
Therapeutics
dopamine
Neurobehavioral Manifestations
glutamates
Preventive Medicine
Cost of Illness
cortexes
impairment
Prefrontal Cortex
Epigenomics
recovery
acids

Keywords

  • Bio-psychosocial-behavioral
  • Cognitive
  • Model
  • Neural circuitry
  • Neurodevelopment
  • Schizophrenia

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

A novel bio-psychosocial-behavioral treatment model in schizophrenia. / Kim, Yong Ku; Choi, Joonho; Park, Seon Cheol.

In: International Journal of Molecular Sciences, Vol. 18, No. 4, 734, 01.04.2017.

Research output: Contribution to journalReview article

@article{012a3b21b4b943198658a9b834500698,
title = "A novel bio-psychosocial-behavioral treatment model in schizophrenia",
abstract = "Despite the substantial burden of illness in schizophrenia, there has been a discrepancy between the beneficial effects of an increased use of antipsychotic medications and achieving limited recovery or remission. Because the focus of the most common antipsychotic medications is on dopamine, which is associated with positive symptoms, there is an unmet need for patients with negative symptoms. Since cognitive and negative symptoms rather than positive symptoms are more closely associated with psychosocial impairments in patients with schizophrenia, the non-dopaminergic systems including glutamate and -aminobutyric acid (GABA) of the prefrontal cortex should be of concern as well. The balance of excitation and inhibition has been associated with epigenetic modifications and thus can be analyzed in terms of a neurodevelopmental and neural circuitry perspective. Hence, a novel bio-psychosocial-behavioral model for the treatment of schizophrenia is needed to account for the non-dopaminergic systems involved in schizophrenia, rather than dopaminergic mechanisms. This model can be understood from the viewpoint of neurodevelopment and neural circuitry and should include the staging care, personalized care, preventive care, reducing the cognitive deficits, and reducing stigma. Thomas R. Insel proposed this as a goal for schizophrenia treatment to be achieved by 2030.",
keywords = "Bio-psychosocial-behavioral, Cognitive, Model, Neural circuitry, Neurodevelopment, Schizophrenia",
author = "Kim, {Yong Ku} and Joonho Choi and Park, {Seon Cheol}",
year = "2017",
month = "4",
day = "1",
doi = "10.3390/ijms18040734",
language = "English",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - A novel bio-psychosocial-behavioral treatment model in schizophrenia

AU - Kim, Yong Ku

AU - Choi, Joonho

AU - Park, Seon Cheol

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Despite the substantial burden of illness in schizophrenia, there has been a discrepancy between the beneficial effects of an increased use of antipsychotic medications and achieving limited recovery or remission. Because the focus of the most common antipsychotic medications is on dopamine, which is associated with positive symptoms, there is an unmet need for patients with negative symptoms. Since cognitive and negative symptoms rather than positive symptoms are more closely associated with psychosocial impairments in patients with schizophrenia, the non-dopaminergic systems including glutamate and -aminobutyric acid (GABA) of the prefrontal cortex should be of concern as well. The balance of excitation and inhibition has been associated with epigenetic modifications and thus can be analyzed in terms of a neurodevelopmental and neural circuitry perspective. Hence, a novel bio-psychosocial-behavioral model for the treatment of schizophrenia is needed to account for the non-dopaminergic systems involved in schizophrenia, rather than dopaminergic mechanisms. This model can be understood from the viewpoint of neurodevelopment and neural circuitry and should include the staging care, personalized care, preventive care, reducing the cognitive deficits, and reducing stigma. Thomas R. Insel proposed this as a goal for schizophrenia treatment to be achieved by 2030.

AB - Despite the substantial burden of illness in schizophrenia, there has been a discrepancy between the beneficial effects of an increased use of antipsychotic medications and achieving limited recovery or remission. Because the focus of the most common antipsychotic medications is on dopamine, which is associated with positive symptoms, there is an unmet need for patients with negative symptoms. Since cognitive and negative symptoms rather than positive symptoms are more closely associated with psychosocial impairments in patients with schizophrenia, the non-dopaminergic systems including glutamate and -aminobutyric acid (GABA) of the prefrontal cortex should be of concern as well. The balance of excitation and inhibition has been associated with epigenetic modifications and thus can be analyzed in terms of a neurodevelopmental and neural circuitry perspective. Hence, a novel bio-psychosocial-behavioral model for the treatment of schizophrenia is needed to account for the non-dopaminergic systems involved in schizophrenia, rather than dopaminergic mechanisms. This model can be understood from the viewpoint of neurodevelopment and neural circuitry and should include the staging care, personalized care, preventive care, reducing the cognitive deficits, and reducing stigma. Thomas R. Insel proposed this as a goal for schizophrenia treatment to be achieved by 2030.

KW - Bio-psychosocial-behavioral

KW - Cognitive

KW - Model

KW - Neural circuitry

KW - Neurodevelopment

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85016951410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016951410&partnerID=8YFLogxK

U2 - 10.3390/ijms18040734

DO - 10.3390/ijms18040734

M3 - Review article

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 4

M1 - 734

ER -